Lyell Immunopharma vs Neonc Technologies Holdings
Lyell Immunopharma and Neonc Technologies Holdings are similar in size: $36,000 and $39,990 of revenue in their latest fiscal years. Lyell Immunopharma grew faster (-41.0% against -51.8%). Neonc Technologies Holdings kept more of each dollar of sales as profit: a net margin of -155404.4% against -762355.6%.
| Latest fiscal year | Lyell ImmunopharmaLYEL, 2025 | Neonc Technologies HoldingsNTHI, 2025 |
|---|---|---|
| Revenue | $36,000 | $39,990 |
| Revenue growth | -41.0% | -51.8% |
| Net income | −$274m | −$62.1m |
| Operating margin | -748344.4% | -145637.5% |
| Net margin | -762355.6% | -155404.4% |
| Return on equity | -87.0% | — |
| Free cash flow | −$151m | −$20.9m |
| Cash | $60.2m | $58,729 |
| Total debt | $0 | $6.0m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 161 | 5 |
| Market value | $252m | $79.4m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 2 buys, 29 sales | 30 buys, 1 sales |